- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04787263
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PML)
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Franco Locatelli, MD, PhD
- Telefonnummer: 2678 0039 066859
- E-mail: franco.locatelli@opbg.net
Undersøgelse Kontakt Backup
- Navn: Francesca del Bufalo, MD
- Telefonnummer: 2739 0039 066859
- E-mail: francesca.delbufalo@opbg.net
Studiesteder
-
-
-
Roma, Italien, 00165
- Rekruttering
- IRCCS Ospedale Pediatrico Bambino Gesù
-
Kontakt:
- Franco Locatelli, MD, PhD
- Telefonnummer: 2678 0039 066859
- E-mail: franco.locatelli@opbg.net
-
Kontakt:
- Francesca del Bufalo, MD
- Telefonnummer: 2739 0039 066859
- E-mail: francesca.delbufalo@opbg.net
-
Ledende efterforsker:
- Franco Locatelli, MD, PhD
-
Ledende efterforsker:
- Francesca del Bufalo, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Diagnosis of CD19 expressing B-ALL or DLBCL or PML and one of the following:
- Patients in 1st relapse, with High-Risk (HR) features including: MLL- rearrangements, E2A/TCF3-PBX1, TCF3-HLF [t(17;19)], hypodiploidy (i.e., <44 chromosomes), TP53 alterations, early (i.e., <30 months from diagnosis)/very early (i.e., <18 months from diagnosis) isolated or combined bone marrow relapse
- MRD > 0.1% after either reinduction therapy or any course of consolidation for relapsed ALL
- Patients with DLBCL or PML in 1st or subsequent relapse, after at least one standard frontline chemotherapy
- Age: 1 year - 25 years for Bcp-ALL and 1-35 years for B-NHL.
- Voluntary informed consent is given. For subjects < 18 year-old their legal guardian must give informed consent. Pediatric subjects will be included in age-appropriate discussion and verbal assent will be obtained for those greater than or equal to 12 years of age, when appropriate.
- Clinical performance status: Patients > 16 years of age: Karnofsky greater than or equal to 60%; Patients < 16 years of age: Lansky scale greater than or equal to 60%.
- Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.
- Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
Exclusion Criteria:
- Pregnant or lactating women
- Severe, uncontrolled active infections
- HIV, or active HCV and/or HBV infection (detection of viral RNA/DNA in blood)
- Life-expectancy < 6 weeks
- Hepatic function: Inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6 x ULN
- Renal function: serum creatinine > 3x ULN for age.
- Blood oxygen saturation < 90%.
- Cardiac function: Left ventricular ejection fraction lower than 45% by ECHO.
- Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject.
- BM blasts > 50% pre-infusion.
- Hyperleukocytosis (greater than or equal to 20,000 blasts/microliter) or rapidly progressive disease that in the evaluation of the investigator would compromise ability to complete study therapy
- Presence of active, grade 2-4 acute or moderate-severe chronic GvHD
- Recurrent or refractory ALL with testicular involvement
Concurrent or recent prior therapies, before infusion:
- Systemic steroids (at a dose > 2 mg/kg prednisone) in the 2 weeks before infusion. Recent or current use of inhaled/topical/non-absorbable steroids is not exclusionary.
- Systemic chemotherapy in the week preceding infusion.
- Anti-thymocyte globulin (ATG) in the 4 weeks preceding infusion.
- Immunosuppressive agents in the 1 week preceding infusion.
- Radiation therapy must have been completed at least 3 weeks prior to enrollment.
- Other anti-neoplastic investigational agents currently administered or within 30 days prior to infusion (i.e. start of protocol therapy);
- Exceptions:
i. There is no time restriction with respect to prior intrathecal chemotherapy, provided that there is complete recovery from any acute toxic effects of such; ii. Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided that they meet all other eligibility criteria; iii. Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided that there has been no increase in dose for at least 2 weeks prior to starting apheresis;
- Patient-derived CD19-CAR_Lenti production failure: vitality of the fresh product <80%, CD3+ cells <80%, CD3+ CAR+ cells <10%, non-sterility in IPC at day 5, endotoxin contamination (> 5 EU/ml) in IPC at day 5, mycoplasma contamination in IPC at day 5, failure of the visual inspection.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: CD19-CAR_Lenti
Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose.
The product will be infused fresh, at the end of manufacturing.
|
Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain.
The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10^6
CAR+ cells/kg.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Phase I - Identification of dose limiting toxicities (DLTs) and recommended dose (RD)
Tidsramme: 4 weeks after CAR T cell infusion
|
Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 5.0
|
4 weeks after CAR T cell infusion
|
Phase I - Identification of recommended dose (RD)
Tidsramme: 4 weeks after CAR T cell infusion of the last patient in the last dose level
|
The recommended dose of CD19-CAR_Lenti will be defined as the maximum tolerated dose (MTD) or the highest dose studied, if an MTD is not reached.
|
4 weeks after CAR T cell infusion of the last patient in the last dose level
|
Phase II - Efficacy
Tidsramme: Up to 6 months after CAR T cell infusion
|
Bone marrow morphological and minimal residual disease complete remission rate at day 28 after infusion for BCP-ALL; Overall Response Rate (CR, CRi, PR and SD) at day 28, day 90 and day 180 after CAR T cells infusion
|
Up to 6 months after CAR T cell infusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Samlet overlevelse (OS)
Tidsramme: Op til 2 år
|
Op til 2 år
|
|
Relapse Rate (RR)
Tidsramme: Up to 2 years
|
Up to 2 years
|
|
Disease-Free Survival (DFS)
Tidsramme: Up to 2 years
|
Up to 2 years
|
|
In vivo persistence/expansion of infused CAR T cell
Tidsramme: Up to 2 years
|
Detection of infused CAR T cell in the peripheral and bone marrow blood
|
Up to 2 years
|
Cytokine profiling
Tidsramme: Up to 10 days after CAR T cell infusion
|
Define serum cytokine profile (Th1/Th2) after T cell infusion and correlation with cytokine release syndrome (CRS)
|
Up to 10 days after CAR T cell infusion
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CD19-CAR_Lenti
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut lymfatisk leukæmi
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeVoksen T Akut lymfoblastisk leukæmi | Barndom T Akut lymfoblastisk leukæmi | Ann Arbor Stage II voksen lymfoblastisk lymfom | Ann Arbor Stage II Childhood Lymfoblastisk Lymfom | Ann Arbor Stage III voksen lymfoblastisk lymfom | Ann Arbor Stage III barndomslymfoblastisk lymfom | Ann Arbor Stage IV... og andre forholdForenede Stater, Canada, Australien, New Zealand
Kliniske forsøg med CD19-CAR_Lenti T cell
-
Zhejiang UniversityYake Biotechnology Ltd.RekrutteringNon-hodgkin lymfom, B-celleKina
-
Zhejiang UniversityYake Biotechnology Ltd.RekrutteringAkut lymfatisk leukæmi | Non-hodgkin lymfom, B-celleKina
-
Second Affiliated Hospital, School of Medicine,...RekrutteringRecidiverende og refraktær B-celle lymfomKina
-
Zhejiang UniversityYake Biotechnology Ltd.RekrutteringVaskulitis | Amyloidose | Autoimmun hæmolytisk anæmi | DIGTE syndromKina
-
Hrain Biotechnology Co., Ltd.Ruijin HospitalIkke rekrutterer endnu
-
Miltenyi Biomedicine GmbHRekrutteringB-celle lymfom refraktær | B-celle lymfom tilbagevendende | Akut lymfoblastisk leukæmi Tilbagevendende | Kronisk lymfatisk leukæmi Tilbagevendende | Refraktær kronisk lymfatisk leukæmiTyskland
-
CARsgen Therapeutics Co., Ltd.Aktiv, ikke rekrutterendeMyelomatoseForenede Stater, Canada
-
ImmunityBio, Inc.Trukket tilbageLymfom | Lymfom, B-celle | Diffust storcellet B-celle lymfom | Storcellet lymfomForenede Stater
-
Hrain Biotechnology Co., Ltd.Second Affiliated Hospital of Nanchang UniversityRekrutteringLymfom i centralnervesystemetKina
-
Xuanwu Hospital, BeijingBeijing Children's HospitalRekruttering